A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ocugen, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 348,900 shares of OCGN stock, worth $327,966. This represents 0.0% of its overall portfolio holdings.

Number of Shares
348,900
Previous 371,300 6.03%
Holding current value
$327,966
Previous $575,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.5 - $1.83 $168 - $614
336 New
336 $0
Q2 2023

Aug 14, 2023

BUY
$0.45 - $0.88 $125,755 - $245,922
279,457 Added 95.1%
573,323 $309,000
Q1 2023

May 15, 2023

BUY
$0.82 - $1.33 $26,684 - $43,280
32,542 Added 12.45%
293,866 $249,000
Q4 2022

Feb 14, 2023

BUY
$1.11 - $1.87 $25,042 - $42,189
22,561 Added 9.45%
261,324 $339,000
Q3 2022

Nov 14, 2022

BUY
$1.75 - $3.1 $347,831 - $616,159
198,761 Added 496.88%
238,763 $425,000
Q2 2022

Aug 15, 2022

SELL
$1.83 - $3.45 $66,793 - $125,921
-36,499 Reduced 47.71%
40,002 $91,000
Q1 2022

May 16, 2022

SELL
$2.34 - $4.72 $865,107 - $1.75 Million
-369,704 Reduced 82.86%
76,501 $252,000
Q4 2021

Feb 14, 2022

SELL
$4.38 - $15.67 $53,440 - $191,189
-12,201 Reduced 2.66%
446,205 $2.03 Million
Q3 2021

Nov 15, 2021

BUY
$6.36 - $8.51 $1.46 Million - $1.95 Million
229,510 Added 100.27%
458,406 $3.29 Million
Q2 2021

Aug 16, 2021

SELL
$5.52 - $15.68 $3.2 Million - $9.09 Million
-579,761 Reduced 71.69%
228,896 $1.84 Million
Q1 2021

May 17, 2021

BUY
$1.66 - $15.81 $1.32 Million - $12.6 Million
794,773 Added 5724.38%
808,657 $5.49 Million
Q4 2020

Feb 16, 2021

BUY
$0.28 - $2.6 $3,887 - $36,098
13,884 New
13,884 $25,000
Q3 2020

Nov 16, 2020

SELL
$0.2 - $0.72 $93,194 - $335,499
-465,972 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$0.22 - $0.46 $74,530 - $155,836
338,774 Added 266.34%
465,972 $103,000
Q1 2020

May 15, 2020

BUY
$0.26 - $0.73 $33,071 - $92,854
127,198 New
127,198 $36,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $204M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.